IceCure Medical Ltd.

Good morning, and thank you for standing by. Currently, all participants are in the listen-only mode. After management's discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to Todd Curley. Please go ahead.

March 31, 2023, and provide an update on recent operational highlights. you may refer to the earnings press release that we issued early this morning. Participating on this morning's call are IceCure Medical's CEO, Eyal Shamir, VP of Business Development and Global Marketing, Alit Busi-Teljour, and the company's CFO and CEO, Roman Simerman. After the prepared comments, management will be available to address your questions. Before we begin, I'll take a moment now to read a statement about four linking statements. This call and the question and answer session that follow it contain forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, could, estimates, and similar expressions or variations of such words are intended to identify forward looking statements. For example, we are using forward-looking statements in this presentation when we discussed during this conference call that we will hold courses or master classes as part of future conferences or our plans to exhibit our technology at future conferences and our belief that there will be a rapid adoption of ProSense for the indication of early stage with high-risk to surgery breast cancer if it receives FDA approval. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by our statements in this presentation. The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, many of which are beyond the control of the company, including those set forth in the risk factors section of the company's annual report on Form 20F, for the year ended December 31st, 2022, filed with the SEC on March 29th, 2023, which is available on the SEC's website at www.sec.gov. The company undertakes an obligation to update these statements for revisions or changes after the call, after the date of this call, except as required by law. I now turn the call over to Ice Care Medical's CEO, Eyal Shamir. Eyal, please go ahead.

Thank you and hello everyone and thanks for joining us today. We will start this review of our significant business development for the first quarter of 2023, followed by an overview of financial results for the three months ended March 31st before opening the call for Q&A. ICO has benefited significantly from the growing awareness and inference in cryoablation, part of a broader trend towards minimally invasive treatment. ProSense, we believe, is the go-to cryoablation system of choice for physicians, including breast surgeons, breast radiologists, and interventional oncologists. Our focused commercialization and marketing efforts in the U.S. are creating great benefits in North America as well as carrying over the momentum into global markets. We continue to engage with the FDA through ongoing discussion that are part of the regulatory submission process. In a major milestone, we received approval in China where our systems and cryoprops are now fully approved for commercial use. An independent study, which I still did not sponsor in any way, was conducted in France using process and another cryoablation technology to treat endometriosis. We were very pleased to learn that the results, which were published in the Journal of Vascular and Interventional Radiology, showing a 92.8% efficacy in avoiding secondary surgery. In what may be one of the most significant milestones for cryoablation in the treatment of breast cancer, The American Society of Breast Surgeons, or ASBRS, the leading medical society comprised of 3,000 healthcare providers for breast surgery, shared its plan for a cryoablation trial at the society's annual meeting. We believe such a trial could potentially establish a new minimally invasive standard for the treatment of early stage breast cancer. It will support our commercialization process at ASBRS members, participate in the trial, gain experience with performing cryoablation treatment, and see the benefits of its use firsthand. I will now turn the call over to Lalit, who will elaborate on our commercial activities.